Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Acute Myelocytic Leukemia Clinical Trial

Official title:

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03796390
• Other study ID #: Daopei CD123CAR-T
• Status: Recruiting
• Phase: Phase 1
• Start date: December 26, 2018
• Est. completion date: June 6, 2021

Study information

• Verified date: January 2019
• Source: Hebei Senlang Biotechnology Inc., Ltd.
• Contact: Peihua Lu, PhD&MD
• Phone: 008618611636172
• Email: peihua_lu[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia. A total of 15 patients are planned to be enrolled following up one year.

Description:

Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many other molecules such as CD22, CD30,BCMA,CD123, etc. may be potential in developing the corresponding CAR-T cells to treat patients whose tumors expressing those markers. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting CD123 in patients with Acute Myelocytic Leukemia. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, disease status after treatment will also be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: June 6, 2021
• Est. primary completion date: November 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subjects with acute myeloid leukemia who voluntarily signed informed consent and met the following criteria:

1. Diagnosed as recurrent or refractory acute myeloid leukemia

2. Tumor cells confirmed CD123 positive by Flow cytometry (FCM) or immunohistochemical detection, and CD123 positive rate >80%

3. Age = 2 years old, and <65 years old

4. Estimated survival time is longer than 3 months from the date of signing the informed consent form

5. KPS = 80 points

6. Important organs function need to meet the following conditions:

1) EF>50%, and there is no obvious abnormality in ECG; 2) SpO2=90%; 3)Cr=2.5ULN; 4)ALT and AST=4ULN, TBil=50µmol/L 7. Subjects with a pregnancy plan must agree to take contraception before the enrollment study and after the study lasts for six months; if the subject is pregnant or suspects of pregnancy, the investigator should be notified immediately 8. Need to stop chemotherapy for at least 2 weeks before collecting the blood to manufacture CAR-T cells.

9. For allogeneic hematopoietic stem cell transplantation subjects, it is necessary to stop the immunosuppressant against GVHD for at least 2 weeks before collecting autologous blood preparation, and if the donor is preparing blood, it is of no influence; 10. If the subject has a history of central nervous system (CNS) leukemia, the tumor cells in the cerebrospinal fluid need to be cleared and the white blood cell count <5 * 10^6 / L ,then can proceed lymphodepletion 11. Subjects who participate in other studies must withdraw other studies for 2 weeks before they can be enrolled.

Exclusion Criteria:

1. Combine other diseases not effectively controlled, including but not limited to persistent or poorly controlled infections, symptomatic congestive heart failure, unstable angina, arrhythmia, poorly controlled lung disease or mental illness

2. There are other active malignant tumors

3. Combined serious infection and can not be effectively controlled

4. Active hepatitis (HBV DNA or hepatitis C virus ribonucleic acid [HCVRNA] detection positive)

5. Human immunodeficiency virus (HIV) infection or syphilis infection

6. Have a history of severe allergies in biological products (including antibiotics)

7. One month after discontinuation of immunosuppressants, allogeneic hematopoietic stem cell transplantation patients still have acute graft versus host response (GvHD)

8. Female subjects are pregnant or lactating

9. Systemic administration of glucocorticoids within one week prior to CAR-T treatment

10. In the past, there was a prolonged QT interval or severe heart disease.

11. Active autoimmune diseases requiring systemic immunosuppressive therapy

12. The investigator believes that it may increase the risk of the subject or interfere with the study results.

Exit criteria:

1. The subjects request to withdraw from the study before CAR-T infusion

2. The subjects seriously violate the protocol

3. Before CAR-T infusion, the following indicators are still abnormal after treatment:

1) EF>50%, and there is no obvious abnormality in ECG 2) SpO2=90% 3)Cr=2.5ULN(the upper limit of normal ) 4) ALT and AST = 4ULN, TBil = 50µmol / L 4.Not enough T cells for manufacture standard CAR-T cells 5. Other serious adverse events occurred

Related Conditions & MeSH terms

• Acute Myelocytic Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Biological:
• CD123 CAR-T cells
Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.

Locations

Country	Name	City	State
China	Hebei Yanda Ludaopei Hospital	Langfang	Hebei

Sponsors (2)

Lead Sponsor	Collaborator
Hebei Senlang Biotechnology Inc., Ltd.	Hebei Yanda Ludaopei Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor load	Tumor load will be quantified with radiology, bone marrow and/or blood samples dependent on diagnosis.	Up to 12 months
Secondary	CAR-T cell persistence	CAR-T cell persistence will be quantified with flow cytometry and qPCR; Percentage of CART cells in BM and copies of car per ug DNA	Up to 12 months